Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Infectious Diseases

• Publication date

  2009-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/599988PMID 19519255PMCID PMC3467007
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland.

  2009cited by this paper
• An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.

  2008cited by this paper
• HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

  2008cited by this paper
• Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

  2008cited by this paper
• Immunobiology of HPV and HPV vaccines.

  2008influential reference
• Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.

  2008cited by this paper
• Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan

  2007cited by this paper
• Evaluation of Two Types of Sponges Used To Collect Cervical Secretions and Assessment of Antibody Extraction Protocols for Recovery of Neutralizing Anti-Human Papillomavirus Type 16 Antibodies

  2007cited by this paper
• Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

  2007cited by this paper
• Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.

  2007cited by this paper
• Antibodies from Women Immunized with Gardasil ® Cross-Neutralize HPV 45 Pseudovirions

  2007cited by this paper
• Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant.

  2007cited by this paper
• Quadrivalent human papillomavirus vaccine.

  2007cited by this paper
• Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

  2006cited by this paper
• Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses

  2006cited by this paper
• Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

  2006cited by this paper
• Chapter 11: HPV vaccines: commercial research & development.

  2006cited by this paper
• High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

  2006cited by this paper
• Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women

  2006cited by this paper
• Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs).

  2006cited by this paper
• B Lymphocyte Activation by Human Papillomavirus-Like Particles Directly Induces Ig Class Switch Recombination via TLR4-MyD881

  2005cited by this paper
• The papillomavirus life cycle.

  2005cited by this paper
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

  2004cited by this paper
• Re: Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles

  2004cited by this paper
• Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

  2004cited by this paper
• Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

  2003cited by this paper
• On natural and artificial vaccinations.

  2003cited by this paper
• Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay

  2003cited by this paper

• A VLPs based vaccine protects against Zika virus infection and prevents cerebral and testicular damage

  2025cites this paper
• Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine

  2025cites this paper
• Assessment of the ability of HPV vaccines to induce neutralizing antibodies based on pseudovirus-based neutralization assay

  2025cites this paper
• Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice

  2024cites this paper
• Updates on cervical cancer prevention

  2023cites this paper
• The HPV Serology Laboratory leads an initiative to standardize and harmonize human papillomavirus serology assays

  2023cites this paper
• Assay Harmonization Study To Measure Immune Response to SARS-CoV-2 Infection and Vaccines: a Serology Methods Study

  2023cites this paper
• Efficacy and Durability of Immune Response after Receipt of HPV Vaccines in People Living with HIV

  2023cites this paper
• Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies

  2022cites this paper
• Immunotherapeutic approaches for HPV-caused cervical cancer.

  2022cites this paper
• Multiplex immunoassay to measure antibody response to nine HPV vaccine types.

  2021cites this paper
• A review on Effectivity of Plant based vaccines in the treatment of viral diseases

  2021cites this paper
• Differential Antibody Response against Conformational and Linear Epitopes of the L1 Proteins from Human Papillomavirus Types 16/18 Is Observed in Vaccinated Women or with Uterine Cervical Lesions

  2021influential citation
• Sex difference in the immunogenicity of the quadrivalent Human Papilloma Virus vaccine: Systematic review and meta-analysis.

  2021cites this paper
• Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.

  2021cites this paper
• Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines.

  2021cites this paper
• Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development

  2020cites this paper
• Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial.

  2020cites this paper
• Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines

  2020cites this paper
• High seroprevalence of multiple high-risk human papillomavirus types among the general population of Bonaire, St. Eustatius and Saba, Caribbean Netherlands.

  2020cites this paper
• Natural and vaccine-induced B cell-derived systemic and mucosal humoral immunity to human papillomavirus

  2020cites this paper
• Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages.

  2020cites this paper
• A prospective cohort study of immunogenicity of quadrivalent human papillomavirus vaccination among Alaska Native Children, Alaska, United States.

  2020cites this paper
• Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals

  2020cites this paper
• Optimization of transfection process to obtain fluorescent Influenza Virus-like particles for drug delivery

  2020cites this paper
• Novel Production of Bovine Papillomavirus Pseudovirions in Tobacco Plants

  2020cites this paper
• Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age

  2020cites this paper
• Comparison of ELISA protocols measuring HPV16 IgG antibodies and evaluation of the association between HPV16 seropositivity and HPV DNA detection

  2019cites this paper
• Human papillomavirus vaccine against cervical cancer: opportunity and challenge.

  2019cites this paper
• Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16–64 years in Puerto Rico

  2018cites this paper
• Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16-64 years in Puerto Rico.

  2018cites this paper
• Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials

  2018cites this paper
• Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development

  2018cites this paper
• Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later – an exploratory study

  2018cites this paper
• Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies

  2017cites this paper
• Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay

  2017cites this paper
• Physicochemical characterization and immunological properties of Pichia pastoris based HPV16L1 and 18L1 virus like particles.

  2017cites this paper
• Functional assessment and structural basis of antibody binding to human 2 papillomavirus capsid 3

  2016cites this paper
• Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD.

  2016cites this paper
• Functional assessment and structural basis of antibody binding to human papillomavirus capsid

  2016cites this paper
• Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes

  2016cites this paper
• Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.

  2016cites this paper
• Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men-United States, 2012-2014.

  2016influential citation
• HPV prophylactic vaccines: Second-generation or first-generation vaccines

  2015cites this paper
• Human papillomavirus epidemiology in men who have sex with men : implications for a vaccine programme at sexual health clinics in the UK

  2015cites this paper
• Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV

  2015cites this paper
• Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003–2010

  2015cites this paper
• Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types.

  2015cites this paper
• Next generation prophylactic human papillomavirus vaccines.

  2015cites this paper
• Do vitamin D levels affect antibody titers produced in response to HPV vaccine?

  2015cites this paper
• HPV and cancer 2 Next generation prophylactic human papillomavirus vaccines

  2015cites this paper
• Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus

  2014cites this paper
• Seroprevalence rates of BKV, JCV, and MCPyV polyomaviruses in the general Czech Republic population

  2014cites this paper
• Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer

  2014cites this paper
• Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay

  2014cites this paper
• Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA

  2014cites this paper
• Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males.

  2014cites this paper
• Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays

  2014cites this paper
• Development of prophylactic human papillomavirus vaccines

  2014cites this paper
• HPV vaccination in head and neck HPV-related pathologies.

  2014cites this paper
• Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Cervical Cancer Vaccine in Malaysian Women Aged 18-35 years: A Randomized Controlled Trial.

  2014cites this paper
• Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities☆

  2014cites this paper
• Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus

  2014cites this paper
• Prevalence and distribution of human papillomavirus genotype in south eastern Italy, in the period 2006-2011: implications for intervention.

  2013cites this paper
• Human papillomavirus vaccination: current indications and future directions.

  2013cites this paper
• Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.

  2013cites this paper
• Mutations in human papillomavirus type 16 L1 hypervariable surface-exposed loops affect L2 binding and DNA encapsidation.

  2013cites this paper
• Individual and geographic disparities in human papillomavirus types 16/18 in high‐grade cervical lesions

  2013cites this paper
• Pseudovirion-binding and neutralizing antibodies to cutaneous human papillomaviruses ( HPV ) correlated with the presence of HPV DNA in skin

  2013cites this paper
• Studies on the influence of human papillomaviruses (HPV) and other biomarkers on the prevalence of oropharyngeal cancer and clinical outcome

  2013cites this paper
• HPV Diagnosis in Vaccination Era

  2013cites this paper
• Virus-like particles for the prevention of human papillomavirus-associated malignancies

  2013cites this paper
• Prevalence and Risk Factors for Neutralizing Antibodies to Human Papillomavirus Types 16 and 18 in HIV-Positive Men Who Have Sex With Men

  2013influential citation
• Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of Gardasil™ in Adult Women

  2013cites this paper
• Multivalent Human Papillomavirus L1 DNA Vaccination Utilizing Electroporation

  2013cites this paper
• Current Indications and Future Directions

  2013cites this paper
• A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls

  2013cites this paper
• Chapter 3 HPV Diagnosis in Vaccination Era

  2013cites this paper
• Pseudovirion-binding and neutralizing antibodies to cutaneous human papillomaviruses (HPV) correlated with the presence of HPV DNA in skin.

  2013cites this paper
• Pseudovirions in the Study of Papilloma- and Polyomaviruses

  2012influential citation
• Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic

  2012cites this paper
• A review of clinical trials of human papillomavirus prophylactic vaccines.

  2012cites this paper
• Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology

  2012cites this paper
• Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types

  2012cites this paper
• Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.

  2012cites this paper
• Vilket vaccin är mest effektivt mot Humant papillomavirus (HPV) -16 och -18, som orsakar livmoderhalscancer - Gardasil eller Cervarix?

  2012cites this paper
• Infección del virus del papiloma humano y cáncer de cuello uterino: distribución de genotipos en mujeres conizadas por lesión escamosa intraepitelial de alto grado (CIN 2-3) y análisis de los cofactores de cáncer de cérvix en Málaga

  2012cites this paper
• Disruption of Centrosome Duplication Control and Induction of Mitotic Instability by the High-Risk Human Papillomavirus Oncoproteins E6 and E7

  2012cites this paper
• Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

  2011cites this paper
• Measured by Pseudovirus Neutralization and Competitive Luminex Assays

  2011cites this paper
• DESARROLLO DE UNA VACUNA PROFILACTICA DE SEGUNDA GENERACION CONTRA EL PAPILOMAVIRUS HUMANO

  2011cites this paper
• Monitoring of human papillomavirus vaccination

  2011cites this paper
• Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines

  2011cites this paper
• Response to: Demarteau N, Standaert B. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. J Med Econ 2010;13:324–38

  2011cites this paper
• Considerations on the clinical application of the human papillomavirus vaccine in Spain

  2011cites this paper
• [Development of a second generation prophylactic vaccine against human papillomavirus].

  2011cites this paper
• The humoral response to Gardasil over four years as defined by Total IgG and competitive Luminex immunoassay

  2011cites this paper
• New Approaches to Prophylactic Human Papillomavirus Vaccines for Cervical Cancer Prevention

  2011cites this paper
• A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2

  2011cites this paper
• Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera

  2011cites this paper